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Abstract: Endoplasmic reticulum calcium homeostasis is involved in several essential cell functions including cell proliferation, protein 
  synthesis, stress responses or secretion. Calcium uptake into the endoplasmic reticulum is performed by Sarco/Endoplasmic Reticu-
lum Calcium ATPases (SERCA enzymes). In order to study endoplasmic reticulum calcium homeostasis in situ in mammary tissue, in 
this work SERCA3 expression was investigated in normal breast and in its benign and malignant lesions in function of the cell type, 
degree of malignancy, and histological and molecular parameters of the tumors. Our data indicate, that although normal breast acinar 
epithelial cells express SERCA3 abundantly, its expression is strongly decreased already in very early non-malignant epithelial lesions 
such as adenosis, and remains low in lobular carcinomas. Whereas normal duct epithelium expresses significant amounts of SERCA3, 
its expression is decreased in several benign ductal lesions, as well as in ductal adenocarcinoma. The loss of SERCA3 expression is cor-
related with Elston-Ellis grade, negative hormone receptor expression or triple negative status in ductal carcinomas. The concordance 
between decreased SERCA3 expression and several histological, as well as molecular markers of ductal carcinogenesis indicates that 
endoplasmic reticulum calcium homeostasis is remodeled during tumorigenesis in the breast epithelium.
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Introduction
Breast carcinoma, which represents 40% of all   cancers 
in women, is a heterogeneous disease with a wide 
variety of pathological entities and range of   clinical 
behaviors.  For  appropriate  clinical  management  a 
complex  set  of  various  clinical,  histological  and 
molecular factors of prognostic and predictive value 
has to be integrated.1 However, although clinicopatho-
logical algorithms are largely used for stratification, it 
is known that breast cancer of patients belonging to 
the same currently used clinically and pathologically 
defined disease groups may display different behav-
iors and response to treatment. It seems therefore, 
that current prognostic factors, although useful, are 
not yet fully sufficient to take into account the molec-
ular and clinical heterogeneity of breast cancer, and 
that further knowledge about molecular differences 
that distinguish normal breast tissue from benign and 
malignant lesions is required for the understanding of 
the disease.
Based  on  work  on  colon  carcinogenesis,2,3 
  neoplasic progression is often regarded as a linear 
multistep process where progressively accumulated 
mutations drive cells sequentially through normal to 
dysplastic to in situ and invasive carcinoma pheno-
types. The complexities of breast molecular carcino-
genesis are, however, reflected by the observations 
that benign tumoral lesions of the breast are not inevi-
tably preneoplastic, that breast carcinoma can arise 
without prior preneoplastic stages, and that the carci-
nomas can arise equally within histologically low or 
high grade premalignant lesions. Breast carcinogen-
esis is therefore now considered as a process in which 
several  parallel  oncogenic  pathways  are  involved 
in a somewhat combinatorial manner, giving rise to 
  several tumor phenotypes with distinct gene expres-
sion profiles, hormone dependency, histological type 
and sensitivity to various types of treatment.1,4–9
The functional units of normal breast epithelium, 
where most breast tumors arise, are the terminal   ductal 
lobular units (TDLU) that are composed of acini and 
intralobular  and  extralobular  terminal  ducts. Acini 
and ducts are layered by an inner (luminal)   epithelial, 
and an outer (basal) myoepithelial cell layer.10   Luminal 
ductal, acinar and basal myoepithelial cells are func-
tionally  and  phenotypically  distinct,10  and  benign, 
as well as malignant breast lesions can also display 
ductal or lobular characteristics. The study of breast 
epithelial  differentiation  and  its  defects  in  benign, 
  premalignant  and  malignant  lesions  is    therefore 
essential for the better understanding of changes that 
occur during neoplastic transformation.
Calcium-dependent cellular signaling is involved 
in  the  regulation  of  many  cellular  functions  such 
as  secretion,  differentiation,  motility,  the  con-
trol  of  cell  proliferation,  as  well  as  survival  or 
apoptosis.11–16    Calcium-induced  cell  activation  is 
critically dependent on the release of calcium from 
the  endoplasmic  reticulum  accumulated  by  Sarco/
Endoplasmic Reticulum Calcium transport ATPases 
(SERCA enzymes). SERCA enzymes are coded by 
three genes (ATP2A1, 2 and 3), the expression and 
alternative splicing of which is tissue dependent and 
developmentally regulated.17,18 Whereas the SERCA1 
and SERCA2a isoforms are expressed in skeletal and 
cardiac   muscle, respectively, the SERCA2b isoform 
is ubiquitous. SERCA3 expression has been reported 
in cells of hematopoietic origin and selected epithe-
lial cells such as colonic and gastric epithelium.17–19 
Interestingly,  the  expression  of  SERCA3  has  been 
previously shown to be negatively regulated by the 
APC/β-catenin/TCF4  oncogenic  pathway  in  colon 
cancer.19 In addition, SERCA3 expression is induced 
during the differentiation of colon and gastric carci-
noma cells,20 and SERCA activity is involved in the 
control of cell differentiation.19,21 These observations 
when  taken  together  show,  that  the  remodeling  of 
ER calcium homeostasis due to the specific loss of 
SERCA3 expression is involved in the establishment 
of the tumoral phenotype in the colon.
Based on these data, in order to explore the role of 
endoplasmic reticulum calcium homeostasis and sig-
naling in breast pathology, in the present work we inves-
tigated the expression of the SERCA3 calcium pump 
in normal breast epithelium, in benign breast lesions 
and in invasive ductal and lobular breast   carcinoma. 
Our data show, that SERCA3 expression undergoes 
significant changes during the neoplastic process in 
the breast and point at the involvement of endoplas-
mic reticulum calcium accumulation in the control of 
breast epithelial differentiation and carcinogenesis.
Materials and Methods
Tissue samples
Formalin fixed and paraffin embedded tissue sections 
from archival biopsies and surgical specimens were Breast tumor calcium pump expression
Breast Cancer: Basic and Clinical Research 2011:5  165
obtained retrospectively from the collection of the 
Pathology Department of Hôpital Lariboisière, Paris, 
France. Samples were processed anonymously and no 
direct patient data were collected. The study did not 
interfere with the routine management and follow-up 
of  cases.  Additional  samples  were  commercially 
obtained in a tissue microarray format (N °Z7020005) 
from BioChain Institute (Hayward, CA, USA, Clini-
Sciences, Montrouge, France) comprising 70 cases 
of all major types of breast carcinoma deposited in 
duplicate. Altogether, a total number of 100 invasive 
lesions and 20 non-invasive lesions were analyzed.
histology
Lesions were analyzed after standard hematoxylin-
eosin-saffron (HES) coloration, and were classified 
according to the WHO classification.22 Carcinomas 
were graded according to the criteria of the grading 
system of Elston and Ellis,23,24 based on tubule differ-
entiation, nuclear pleomorphism and mitotic count.
immunohistochemistry
Immunohistochemistry  was  performed  on  deparaf-
finized formalin-fixed sections using an indirect ABC- 
peroxidase method revealed with 3,3′diaminobenzi-
dine (DAB) as chromogene.   Endogenous peroxidase 
activity was blocked by incubation in 3% hydrogen 
peroxide  in  phosphate-buffered  saline  for  10  min-
utes.  Immunohistochemistry  was  performed  with 
an automated immunostainer system (Benchmark®, 
Ventana Medical Systems, Illkirch, France) using pri-
mary antibodies raised against E-cadherin, estrogen 
receptor, progesterone receptor, Ki-67, and HER-2 
(Table 1). HER-2 immunostaining was done in par-
allel with negative and 3+ positive external controls 
calibrated  by  in  situ  hybridization.  For  each  anti-
gen, omission of the primary antibody and replace-
ment by an isotype-matched irrelevant antibody were 
used as negative controls and these gave no   staining. 
  Staining for SERCA3 was performed using the clone 
2H3  (H00000489-MO1)  monoclonal  mouse  anti-
SERCA3  antibody  (IgG2a  kappa)  from  Abnova 
(Tebu-bio,  Le  Perray  en  Yvelines,  France)  raised 
against a GST-tagged peptide sequence encompass-
ing the 501–621 amino acid fragment of SERCA3, at 
3 µg/ml final concentration diluted in Dako Real® anti-
body diluent (Dako France S.A.S., Trappes, France). 
Briefly,  after  inhibition  of  endogenous  peroxydase 
and antigen retrieval of deparaffinized sections by a 
tris-(hydroxymethyl)-  aminomethane-based  antigen 
retrieval reagent (Ventana CC1 cell conditioning solu-
tion) at 95–100 °C for 30 minutes, slides were incu-
bated for 30 minutes at 37 °C with the anti-SERCA3 
antibody, and   staining was revealed using the Ventana 
I-View Biotin-  Ig-streptavidin-biotin-horseradish per-
oxydase system with copper enhancement, accord-
ing  to  the  instructions  of  the  manufacturer.  Slides 
were  counterstained  with  hematoxylin  and  bluing 
agent (  Ventana Medical Systems, Illkirch, France). 
For  estrogen  rec  eptor  (nuclear  labeling),  proges-
terone  receptor  (nuclear  labeling),  SERCA3  (cyto-
plasmic  labeling)  and  HER2  (membrane  labeling), 
the intensity of immunostaining was semi-quantita-
tively evaluated using a 4 grade scale (0 to 3+) and 
by determining the percentage of stained cells. For 
Ki-67,  percentage  of  positive  cells  (nuclear  label-
ing) was evaluated using a 3 grade scale (S1 , 15%, 
15% # S2 , 40%, S3 $ 40%). For SERCA3 immu-
nostaining, endothelial cells and   lymphocytes   present 
in the sections were used as   internal positive control. 
For estrogen and   progesterone receptors, in addition 
to external positive controls, normal breast structures 
present in the specimens served as internal positive 
controls.
Statistical analysis
Non-parametric  statistical  analysis  was  performed 
using  Kruskal-Wallis  and  Mann-Whitney  tests  for 
Table 1. Antibodies used in this study for the characterization of breast lesions.
Antibody supplier catalog number Dilution
e-cadherin DakoCytomation, glostrup, Denmark M3612 1/50
estrogen receptor novocastra, newcastle upon Tyne, UK nCL-eR-6F11 1/50
Progesteron receptor Coulter-immunotech, Marseille, France 2147 1/50
Ki-67 DakoCytomation M-7240 1/50
heR-2/C-erbB-2 DakoCytomation A-0485 1/3500
note: Dilutions and sources of the antibodies used in this study for the immunohistochemical characterization of breast lesions.Papp and Brouland
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  comparison of quantitative variables using the XLSTAT 
2010 software (Addinsoft, Paris, France). A p-value 
less than 0.05 was considered as significant.
Results
normal breast
SERCA3  labeling  in  normal  breast  epithelium  is 
located in the cytoplasmic area and appears finely 
granular, corresponding to the endoplasmic reticulum 
on the light microscopic level. As shown in Figure 1, 
SERCA3 labeling in normal breast structures is mark-
edly heterogeneous. The strongest labeling (+++) is 
seen in luminal cells of acini, which express SERCA3 
at levels similar to that observed in lymphocytes and 
endothelial cells present in the samples. In marked 
contrast with acinar luminal cells, SERCA3 expres-
sion in terminal duct luminal epithelium is very weak 
to weak (0/+ to +; Figure 1, Panels A, B and C green 
arrows), whereas in larger ducts SERCA3 labeling is 
somewhat more heterogeneous (Fig. 1, Panel D), and 
varies from weak to moderate (+ to ++).   Myoepithelial 
cells  in  acinar,  as  well  as  in  ductal  structures  are 
  consistently negative.
non-invasive lesions
Adenosis is a benign condition without increased rela-
tive risk of cancer, where the lobules are enlarged and 
composed of small acini made of epithelial cells and 
myoepithelial cells. In sharp contrast with   normal acini 
(Fig. 2, Panel A), epithelial cells in   adenosis exhibited 
a very weak or negative staining for SERCA3 (Fig. 2, 
Panels B and C).
Apocrine metaplasia is a common benign condi-
tion without increased relative risk of cancer, found 
in female breast after the age of 30 years. The lesion 
is  composed  of  cuboidal  or  flat  cells  that  form  a 
  single luminal layer or blunt papillae. Nuclei appear 
homogeneous and regular without atypia. As shown 
in Figure 3, SERCA3 is weakly and homogeneously 
expressed in the cytoplasmic area of the cells, whereas 
myoepithelial cells are negative.
Columnar cell lesions
Columnar cell changes without atypia are character-
ized by dilation of terminal ductal lobular units lined 
by  columnar  epithelial  cells  with  basally  oriented 
nuclei  and  luminal  cytoplasmic  tufts  and  ranging 
from one to two cell layers.
Columnar cell changes with atypia (ductal intra-
epithelial neoplasia; DIN 1A) are characterized by 
a stratified epithelium which may form micropap-
illary  or  fenestrated  structures.22  Although  known 
since a long time, these lesions are being increas-
ingly detected as mammographic calcifications, and 
have  been  shown  to  be  associated  with  invasive 
  carcinomas, usually of the lobular type.25 As shown 
in    Figure  4,  SERCA3  expression  in  columnar 
changes with (Panel B), or without atypia (Panel A) 
is moderate and somewhat heterogeneous with   apical 
reinforcement.
Ductal  hyperplasia  of  the  breast  is  a  common 
lesion characterized by an increase in the cellularity 
of duct epithelium leading to a partial or complete 
obliteration of the duct lumen.
In usual ductal hyperplasia (low risk DIN) nuclei 
may seem to overlap, and nucleoli remain inconspic-
uous even when hyperplasia is florid.22 This entity is 
  considered to carry a very low to low relative risk of 
cancer (RR: 1.2 to 2).
In  comparison,  atypical  ductal  hyperplasia 
(DIN 1B)22 is considered to carry a moderate relative 
risk (RR: 4 to 5) of subsequent invasive carcinoma. 
It exhibits cytological atypia such as enlarged hyper-
chromatic nuclei, clumped irregular chromatin and 
enlarged pleomorphic nucleoli.
AB
CD
Figure 1. expression of SeRCA3 in normal breast structures. Luminal 
cells of acini strongly express SeRCA3. intensity of labeling is compa-
rable to that of endothelial cells (panel c, red arrows) or lymphocytes 
(panel D, small green arrows). SeRCA3 labeling in terminal duct luminal 
epithelium is very weak to weak (panels A, B and c, large green arrows). 
in larger ducts SeRCA3 labeling is somewhat more heterogeneous, and 
varies from weak to moderate (panel D). Myoepithelial cells in acinar, 
as well as ductal structures are negative. Original magnification: ×20 
 ( panels A and B), ×40 (panels c and D).Breast tumor calcium pump expression
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homogenous chromatin with   inconspicuous   nucleoli. 
In some cases, proliferative cells may appear larger 
and  more  pleomorphic  (LIN  3).  In  all  grades, 
SERCA3 expression is always weaker than in normal 
acini (Fig. 6).
invasive lesions
Invasive breast carcinoma can be graded based on 
histological criteria. The current three tiered classi-
fication of Elston and Ellis, based on the combined 
grading of tubule formation, nuclear pleomorphism 
and mitotic activity is widely used in clinical prac-
tice, and is prognostically, as well as therapeutically 
pertinent.23,24 Invasive ductal and lobular carcinomas 
always  exhibit  a  decreased  labeling  for  SERCA3 
when compared to normal acini.
When investigated in invasive ductal carcinomas, 
an inverse relationship could be observed between 
SERCA3  expression  and  Elston-Ellis  grade  (EE). 
As  shown  in  Figures  7  and  8,  SERCA3  expres-
sion  decreases  significantly  among  EE  groups 
(  Kruskal-Wallis test, p = 0.012). SERCA3 expres-
sion  is  significantly  higher  in  Elston-Ellis  groups 
EE1 (mean = 1.350) and EE2 (mean = 0.833), than in 
group E3 (mean = 0.644; Fig. 8, Panel A). Although 
SERCA3  expression  does  not  differ  significantly 
ABC
Figure 2. SeRCA3 expression in adenosis. expression is very weak or negative in adenosis (panels B and c), in contrast with normal acini (panel A). 
Original magnification: ×20.
As shown in Figure 5, SERCA3 expression in duc-
tal hyperplasia is always weaker than in normal acini 
and its intensity is similar to that of normal ducts, 
independently from the presence (Fig. 5, Panels C 
and D) or absence of atypia (Fig. 5, Panels A and B).
In situ ductal carcinomas are classified as DIN 1C, 
2 and 3 according to the degree of the proliferation 
and/or cytological features.22 As shown in Figure 5 
(Panels E and F), the expression of SERCA3 is sig-
nificantly lower than in normal acini or lymphocytes 
and is globally of moderate intensity.
Lobular  in  situ  neoplasia  (LIN)  are  located  in 
terminal duct-lobular units and are characterized by 
conserved lobular architecture whereas the acini of 
one or more lobules are distended by a loosely cohe-
sive monomorphic cell proliferation.22 According to 
the extent and degree of the proliferation and/or cyto-
logical features, LIN is graded into LIN 1, LIN 2 and 
LIN 3. Cytologically, proliferative cells are usually 
of small size, with round nuclei (LIN 1 and 2) and 
Figure 3. SeRCA3 expression in apocrine metaplasia. expression is 
weak and homogeneous in the cytoplasmic area of the cells.   Lymphocytes 
are strongly positive. Original magnification: ×40.
AB
Figure 4. SeRCA3 expression in columnar changes with (panel B) 
or without atypia (panel A). expression is moderate and somewhat 
heterogeneous with apical reinforcement. Original magnification: ×20 
 ( panel A), ×40 (panel B).Papp and Brouland
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between groups EE1 and EE2 (Mann-Whitney test, 
p  =  0.114),  as  shown  in Figure  8,  Panel  B,  when 
groups EE1 and EE2 are pooled for analysis, a highly 
significant  difference  can  be  observed  when  com-
pared to group EE3 (Mann-Whitney test, p = 0.006).
SERCA3 expression of invasive lobular carcino-
mas was always weaker than that of normal acini, as 
shown in Figure 9. No significant differences could 
be  observed  among  various  Elston-Ellis  groups 
in  these  lesions  (Kruskal-Wallis  test,  p  =  0.056), 
although a tendency of increased SERCA3 expres-
sion could be observed between EE1 (m = 1.063) and 
EE2 (m = 1.542) groups, and a decrease from EE2 
to EE3 (m = 0.167). SERCA3 expression does not 
differ between the groups EE1 and EE2 according to 
the Mann-Whitney test ( p = 0.274). However, when 
groups EE1 and EE2 were pooled, they significantly 
differed  from  the  group  EE3  (Mann-Whitney  test, 
p = 0.033, not shown).
Regarding individual parameters of the Elston-  Ellis 
grading system (ie, tubule formation, nuclear pleo-
morphism and mitotic activity), the loss of SERCA3 
expression in ductal carcinomas varies significantly 
among nuclear grade (NG) groups (Kruskal-  Wallis 
test, p = 0.0003; Fig. 10, Panel A). SERCA3 expres-
sion is significantly higher in NG groups 1 and 2 
AB
CD
EF
Figure 5. SeRCA3 expression in epithelial hyperplasia with (panels c 
and D), or without atypia (panels A and B) and in ductal carcinoma 
in situ (panels e and F). expression is moderate, and always weaker 
than in normal acini or lymphocytes. in panel A, epithelial hyperplasia 
(red arrow) can be distinguished from columnar change (green arrow) by 
the lack of apical reinforcement of SeRCA3 staining in the former. Origi-
nal magnification: ×40 (panels A, B and F), ×20 (panels c, D and e).
AB
CD
Figure 6. SeRCA3 expression in lobular in situ neoplasia (Lin).   expression 
is always weaker than in normal acini, and seems to slightly increase with 
increased atypia. (panel A: Lin 1, panels B and c: Lin 2, panel D: Lin3). 
Original magnification: ×20 (panel A), ×40 (panels B, c and D).
AB
CD
EF
Figure 7. SeRCA3 expression in invasive ductal carcinomas.   expression 
is weaker than in normal acini. The decrease of SeRCA3 expression 
correlates with the increase of elston-ellis (ee) grade. panel A: tubular 
  carcinoma (very well differentiated, ee grade i); panel B: ductal carci-
noma (ee grade i); panels c and D: ee grade ii ductal carcinomas; pan-
els e and F: EE grade III ductal carcinomas. Original magnification: ×20 
(panels A, c and e), ×40 (panels B, D and F).Breast tumor calcium pump expression
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(m = 1.906 and 1.060, respectively), than in NG group 
3 (m = 0.552). NG1 and NG2 groups do not differ sig-
nificantly when analyzed by the Mann-Whitney test 
( p = 0.062). However, when NG1 and NG2 groups 
were  pooled  and  compared  to  NG3,  a  highly  sig-
nificant difference could be obtained by the Mann-
Whiney test ( p = 0.0001; Fig. 10, Panel B).
On  the  other  hand,  SERCA3  expression  does 
not  vary  significantly  among  tubule  differentiation 
(TG)  grades  as  measured  by  the  Kruskal-Wallis 
test (  p = 0.069, not shown), although a tendency of 
decreased expression can be observed with decreased 
tubule differentiation (ie, increased TG). However, 
when TG1 and TG2 groups are pooled, a significant 
decrease of SERCA3 expression can be observed in 
the TG3 group by the Mann-Whitney test ( p = 0.035; 
Fig. 11, Panel A).
In  order  to  investigate  the  correlation  between 
SERCA3  expression  and  mitotic  activity,  three 
grades for Ki-67 expression (S1, S2 and S3) were 
used,   corresponding to less than 15%, 15%–39% and 
40%–100% Ki-67 positivity, respectively. SERCA3 
expression did not differ significantly among S groups 
(Kruskal-Wallis test, p = 0.668, not shown).
In order to further analyze the correlation between 
SERCA3  expression  and  tumor  histology,  samples 
were stratified simultaneously for nuclear grade (NG) 
and  Ki-67  expression  (S),  and  groups  that  display 
low,  intermediate  and  high  grades  simultaneously 
for nuclear grade and for mitotic activity (NG1/S1, 
NG2/S2 and NG3/S3, respectively) were established. 
As shown in Figure 11, Panel B, using this combined 
stratification  scheme,  a  highly  significant  correla-
tion could be observed between decreased SERCA3 
expression  and  NG/S  groups  (Kruskal-Wallis  test, 
p = 0.008).
Analysis  of  estrogen  (ER)  and  progesterone 
  receptor (PR) expression is widely used in the clinical 
management of breast carcinoma, and has also been 
shown to be relevant for the molecular classification 
of tumors.4–6,26,27 As shown in Figure 12, when inva-
sive ductal carcinomas were stratified according to 
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Figure 8. Statistical analysis of SeRCA3 expression according to elston-ellis (ee) grade in ductal carcinomas. panel A: SERCA3 expression significantly 
decreases from ee i to ee iii groups (Kruskal-Wallis test, p = 0.012). Although EE I and EE II groups don’t differ significantly, when EE I and EE II groups 
are pooled (panel B), a significant difference is observed when compared to EE III tumors (Mann-Whitney test, p = 0.006). Box plot shows median.
AB
CD
Figure 9. SeRCA3 expression in invasive lobular carcinomas. panel A:   
ee grade i, panel B: ee grade ii lobular carcinomas. panels c and D: 
  pleomorphic ee grade iii lobular carcinomas. SeRCA3 expression is vari-
able, but always markedly decreased when compared to normal acini or 
normal lymphocytes. Original magnification: ×40.Papp and Brouland
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estrogen (Mann-Whitney test, p = 0.007; Panel A), 
or progesterone receptor expression (Mann-Whitney 
test,  p  =  0.041;  Panel  B),  significantly  higher 
SERCA3 expression could be observed in estrogen or 
  progesterone receptor positive tumors. When double 
hormone receptor negative (HR0) and double positive 
(HR+) tumors were compared, SERCA3 expression 
was also significantly higher in double positive tumors 
(  Mann-Whitney test, p = 0.003; Fig. 12, Panel C).
In order to explore the combined effect of hor-
mone receptor status (HR) and nuclear grade (NG), 
invasive  ductal  carcinomas  were  stratified  simul-
taneously  according  to  nuclear  grade  and  hor-
mone receptor expression. When tumors with low/
medium nuclear grade (NG1/2) that express hormone 
  receptors  (HR+)  were  compared  to  high  nuclear 
grade, hormone  receptor negative (NG3/HR0) tumors, 
a  highly    significantly  decreased  SERCA3  expres-
sion could be observed in high nuclear grade, hor-
mone receptor negative tumors (Mann-Whitney test, 
p = 0.00035; Figure 13, Panel A). Moreover, when 
tumors with low proliferation index and simultane-
ous positive hormone receptor status (HR+/S1) were 
compared  to  highly  proliferative,  hormone  recep-
tor negative (HR0/S2,3) tumors, a highly significant 
decrease of SERCA3   expression could be observed 
in  the  latter  (  Mann-Whitney  test,  p  =  0.00025; 
  Figure 13, Panel B). When HER-2   expression was 
studied, SERCA3 expression did not differ signifi-
cantly between HER-2 0/+ and HER-2 +++ tumors 
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Figure 10. Statistical analysis of SeRCA3 expression in invasive ductal carcinomas according to nuclear grade (ng). panel A: SeRCA3 expression 
decreases significantly with increasing nuclear pleomorphism (NG1 to NG3; Kruskal-Wallis test, p = 0.0003). panel B: When ng1 and ng2 groups are 
pooled and compared to NG3, SERCA3 expression is significantly decreased in NG3 tumors when analyzed with the Mann-Whitney test (p = 0.0001).
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Figure 11. Statistical analysis of SeRCA3 in invasive ductal carcinomas. panel A: Although SERCA3 doesn’t vary significantly according to tubular dif-
ferentiation (Tg) among Tg1, 2 and 3 grades (Kruskal-Wallis test, p = 0.069, not shown), when TG1 and TG2 tumors are pooled, a significant decrease of 
SeRCA3 expression is observed in Tg3 tumors (Mann-Whitney test, p = 0.035). panel B: Statistical analysis of SeRCA3 expression in invasive ductal car-
cinomas stratified simultaneously for nuclear grade (NG) and proliferation index as detected by Ki-76 staining (S). Although SERCA3 expression doesn’t 
differ significantly according to mitotic activity alone (not shown), a significant decrease of SERCA3 expression is observed when NG1/S1, NG2/S2 and 
ng3/S3 tumors are compared (Kruskal-Wallis test, p = 0.008). Box plot shows median.Breast tumor calcium pump expression
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(Mann-Whitney test, p = 0.883; not shown). Inter-
estingly, on the other hand, there was a significant 
decrease  of  SERCA3  expression  (Mann-Whitney 
test, p = 0.004; not shown) in triple negative tumors 
(HR0, HER-2 0; m = 0.333) when compared to all 
other tumor types as a group (m = 0.897).
Discussion
Data presented in this work show, for the first time, 
that SERCA3 protein is expressed in normal breast tis-
sue, with the highest expression levels found in normal 
lobular epithelial cells. SERCA3 expression was also 
observed, although at a lower level, in luminal ductal 
cells as well, whereas myoepithelial cells were consis-
tently negative. This indicates that SERCA3 constitutes a 
new   phenotypic marker that displays a cell-type specific 
expression pattern in the normal mammary gland.
Of  particular  interest,  we  show  that  SERCA3 
expression in acini markedly decreases already in very 
early and common lobular lesions such as   adenosis 
and  lobular  hyperplasia  without  atypia  which  are 
non-obligatory low risk precancerous lesions. This 
observation indicates that fully differentiated normal 
breast acinar epithelium possesses a specialized endo-
plasmic reticulum calcium uptake system, which, as 
reflected by the loss of SERCA3 expression, under-
goes significant remodeling at a very early step of 
hyperplasia/dysplasia.
Calcium-dependent signal transduction constitutes 
a key component of intracellular signaling   networks 
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Figure 13. Statistical analysis of SeRCA3 expression in invasive ductal carcinomas. panel A: When tumors are stratified simultaneously according to 
nuclear grade (NG) and hormone receptor expression (HR), SERCA3 expression is significantly decreased in high nuclear grade, hormone receptor nega-
tive (ng3/hR0) tumors when compared to low nuclear grade, hormone receptor positive (ng1/hR+) tumors (Mann-Whitney test, p = 0.00035). panel B: 
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that control cell growth, differentiation and survival. 
Calcium-dependent cell activation is initiated by the 
release of calcium from the endoplasmic reticulum 
by  second  messengers  such  as  inositol-1,4,5-  tris-
phosphate.12,14 Calcium accumulation in this organelle 
depends entirely on the activity of SERCA enzymes. 
Therefore, the extent, the spatiotemporal characteris-
tics, frequency and amplitude of calcium release from 
the endoplasmic reticulum  are critically dependent 
upon, and modulated by, SERCA-dependent calcium 
transport.28–33  SERCA  activity  therefore  constitutes 
a  major  negative  feedback  mechanism  on  calcium 
mobilization from the organelle.
It has been shown earlier that SERCA3 expres-
sion  undergoes  major  changes  during  colon  and 
gastric carcinogenesis.19,20 Whereas SERCA3 is abun-
dantly expressed in gastric and colonic epithelium,20 
SERCA3 expression is decreased in colon adenomas, 
and lost in adenocarcinomas.19 In addition, it has been 
shown, that the induction of cell differentiation by 
histone deacetylase inhibitors, as well as the inhibi-
tion of the APC/β-catenin-TCF-4 oncogenic pathway 
by dominant negative TCF-4 lead to the induction 
of the expression of SERCA3 in colon cancer cells 
in  vitro.19,20  SERCA3  expression  is  correlated  also 
with the state of differentiation of various lymphoid34,35 
and myeloid36,37 leukemia cells, and the direct phar-
macological  modulation  of  SERCA  activity  can 
induce growth factor independence, growth arrest or 
differentiation in a cell-type dependent manner.19,21,40 
These observations, when taken together indicate that 
SERCA-dependent  calcium  sequestration  into  the 
endoplasmic reticulum can modulate cell growth and 
differentiation in various cell types.
Epidemiologic,  as  well  as  experimental  studies 
indicate that calcium plays an important role in breast 
cancer prevention and in the control of breast   cancer 
cell  growth.38,39  The  observation  that  endoplasmic 
reticulum calcium pump expression becomes anoma-
lous already in very early non-obligatory   precancerous 
lesions indicates that proper calcium uptake into the 
organelle is involved in the establishment and mainte-
nance of the fully differentiated breast acinar pheno-
type, and suggests that a previously unknown defect 
of calcium accumulation into the endoplasmic reticu-
lum, related to the loss of SERCA3 expression, may 
be involved in the formation of early/premalignant 
steps of breast tumorigenesis.
When investigated in invasive ductal or lobular 
breast  carcinoma,  SERCA3  expression,  although 
variable, was always decreased when compared to 
normal acini, and in several cases was below detec-
tion  limits.  While  tubular  carcinoma,  a  histologi-
cally well differentiated lesion, displayed SERCA3 
expression  almost  similar  to  normal  acini,  and 
  stronger than normal ducts, SERCA3 expression in 
invasive ductal carcinoma was lower than in normal 
controls (lymphocytes, endothelial cells and normal 
acini). SERCA3 expression in invasive ductal car-
cinoma  was  inversely  proportional  to  Elston-Ellis 
(EE) grade, as well as to individual components of 
the EE grading system, with the strongest correlation 
being observed with nuclear grade. Moreover, when 
tumors  were  stratified  simultaneously  for  nuclear 
grade (NG) and proliferative activity (S), a highly 
significant  correlation  could  be  observed  between 
grade and SERCA3 expression among the NG1/S1, 
NG2/S2 and NG3/S3 groups. In benign ductal lesions 
(  columnar  changes,  apocrine  metaplasia,    ductal 
hyperplasia with or without   atypia), the expression of 
SERCA3 was decreased when compared to normal 
controls and remained heterogeneous in the range of 
weak to moderate expression levels.
When  investigated  in  the  context  of  estrogen 
and  progesterone  receptor  expression,  the  loss  of 
SERCA3 expression was found to be correlated with 
hormone receptor negative status in invasive ductal 
  carcinomas, and an even stronger correlation could be 
seen when lesions were stratified simultaneously for 
hormone receptor status and nuclear grade. In addition, 
SERCA3 expression was also significantly decreased 
in triple negative (HR0, HER-2 0) carcinomas.
Taken  together,  data  presented  in  this  work 
show  that  normal  acinar  differentiation  in  breast 
is  associated  with  strong  SERCA3  expression. 
This is drastically decreased already at the   earliest 
stages  of  morphologically  detectable  anomalies 
of   normal acinar architecture, and remains low at 
further stages of lobular carcinogenesis.   Regarding 
ductal  pathology,  we  show  that  although  normal 
breast ducts express SERCA3 at significant levels, 
its expression is comparable or decreased in early 
benign ductal lesions. In invasive ductal carcinoma 
SERCA3  expression  is  inversely  correlated  with 
nuclear grade and proliferative activity, as well as 
with hormone receptor expression. SERCA3 loss Breast tumor calcium pump expression
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is the most marked in high nuclear grade, highly 
  proliferating,  hormone  receptor  negative  tumors. 
The correlation of the degree of SERCA3 expres-
sion  with  several  established  markers  of  breast 
  cancer biology connects, for the first time,   abnormal 
endoplasmic reticulum calcium pump expression to 
breast tumorigenesis.
Cellular calcium homeostasis is maintained by 
a functionally interconnected network of calcium 
pumps,  calcium  channels  and  calcium  binding 
proteins. The activity of many components of this 
network is regulated by calcium itself in a concen-
tration-dependent manner, and interconnectedness 
and partial functional redundancies of the compo-
nents are typical of the cellular calcium homeostatic 
“toolkit”.14,33 Decreased SERCA3 expression may 
thus have complex consequences on global cellular 
calcium homeostasis, cell survival and responsive-
ness to external stimuli. SERCA3 has been shown 
earlier to be associated with the inositol-1,4,5-tris-
phosphate-mobilisable  sub-compartment  of  the 
endoplasmic reticulum in platelets.41 It is tempting to 
speculate that SERCA3 loss in breast epithelial cells 
may also lead to decreased calcium accumulation 
into  the  inositol-1,4,5-tris-phosphate-  mobilisable 
calcium pool, leading to the acquisition by the cell of 
a more autonomous signaling configuration42 with a 
decreased or lost capacity to respond to extracellular 
stimuli that signal via inositol-1,4,5-tris-phosphate-
induced calcium mobilization. These effects may 
be  explored  in  further  investigations  using,  for 
example,  genetically  engineered    calcium  indica-
tors (GECIs43) expressed in   mammary   epithelium 
in  model  systems  that  recapitulate  the  formation 
and  progression  of  benign  and  malignant  breast 
tumors.
In  conclusion,  observations  presented  in  this 
work indicate that endoplasmic reticulum calcium 
pump function may be involved in the process of 
breast tumorigenesis already at a very early stage. 
  Detection of SERCA3 expression may prove   useful 
for  the  immunophenotypic  characterization  of 
benign and malignant lesions. A better   understanding 
of  the  molecular  implications  of  the  endoplasmic 
reticulum  calcium  homeostatic  defect  reflected 
by the loss of SERCA3 expression may open new 
  avenues in the understanding of early steps of breast 
tumorigenesis.
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